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A 23-year-old spraypainter developed contact dermatitis and respiratory difficulty characerzed
bysmall airways obstruction shordyafterthepolyfunctional aziridinecrosslinkeraX-100began
to be used in his workplace as a paint activator. The symptoms resolved after he was removed
from the workplace and was treated with inhaled and topical steroids. Painters may have an
incresed riskofahma due toexposure to avariety ofagents, such as isocynates, alkyd resins,
and chromates. This case illu arates the importance ofusing appropriateworkpractices and per-
sonal protective equipment to minimize exposure. Occupational as a is diagnosed by a histo-
ry ofwork-related symptoms and eposure to known causative agents. The diagosis is con-
firmed byserial pulmonary function testing orinhalational challenge tin. Therisk ofasthma
attributable to occupational exposures is probably undepad due to underreporting and
to inappropriate use ofnarrow definitions ofexpsure in epidemioloic studes ofattributable
risk Key words aziridine, contact dermatitis, occpaional asthma, personal prot equip-
ment, spraypainting. EnvronHeal Peect107:599-601 (1999). [Online 16june 19991
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Case Presentation
A 23-year-old spray painter developed der-
matitis and difficulty breathing after a new
paint additive began to be used in his work-
place in late December 1992. The rash began
on his hands and progressed to his forearms,
legs, and neck. The initial diagnosis was tinea
corporis, and then asteototic dermatitis with
nummular lesions. In January 1993, he was
given nasal beclomethasone for congestion
and an inhaler forbreathingdifficulties.
In February 1993, the patient was treated
for bronchitis. By March, the rash was worse
and hewas given an albuterol inhaler for con-
tinuedwheezing. He also had several episodes
of eye irritation and redness and some peri-
orbital and unilateral facialswelling.
During a 2-week vacation in July, the
patient needed the bronchodilator less often.
The rash on his hand appeared unchanged,
buthe noted improvement in thepruritis and
in the backofhis neckandlegs.
In August 1993, the patient was referred
to occupational medicine for the dermatitis.
He brought material safety data sheets for
water-based low-bake enamel paints. The new
paint additive was a polyfunctional aziridine
cross-linker, CX-100 (1). At this time, the
patient was using diphenhydramine, inhaled
albuterol, and topical triamcinolone. He had
a scaly erythematous fissured rash on the dor-
sum of the hands, and palmar, forearm, and
facial erythema. An erythematous, scaly area
extended over the posterior neck and upper
back, and he had an intertriginous rash
under the abdominal skin fold and an ery-
thematous rash with circumscribed, raised
edges on the scrotum and upper thighs. The
patient's legs had erythematous papules and
confluent areas of dermatitis. His nasal
mucosa was boggy and pink, with a milky-
colored discharge. There were bilateral expi-
ratory wheezes throughout the lung fields,
and his peak expiratory flow rate was 710
L/min. The diagnosis was a delayed hyper-
sensitivity contact dermatitis, probably due
to the aziridine cross-linker. Occupational
asthma was considered because of the rela-
tion ofsymptoms to exposure onset and his
reduced symptoms during a vacation, even if
changes were not noted onweekends.
Whileworking, the patient's forced vital
capacity (FVC) was 4.7 L (97% ofpredict-
ed). His forced expiratory volume in the
firstsecond (FEVy) was 3.74 L (87% ofpre-
dicted). The ratio of FEV1 to FVC was
0.79. The patient's midexpiratory flow was
3.13 L/sec (62% of predicted). After the
patient used bronchodilators, his FEV1 was
unchanged, but the midexpiratory flow rate
increased by 19%. This pattern was consis-
tent with mild small airways disease. The
patient had a 5% cross-shift drop in the
peakexpiratory flow rate onworkdays. After
he was removed from the workplace, the cor-
respondingpeakflow rates rose.
By September, the patient had been out
of work for 1 week. His dermatitis had
improved and his lungs were clear. He then
left thisjob permanently.
In October, the patient was given a
methacholine challenge test that showed a
provocative concentration resulting in a 20%
drop in the FEV1 (PC20) of 0.5 mg/mL
(with < 8 mg/mL considered diagnostic of
hyperreactive airways). The patient's dermati-
tis was resolved in all areas but the hands. He
used a bronchodilator in the morning for
chest tightness and cough and triamcinolone
two puffs twice per day; he used fluocinonide
cream forhis hands.
In late October, the patient was pre-
scribed triamcinolone cream and gloves at
night for a vesicular eruption on his fingers.
He discontinued inhaled steroids in late 1993
because ofimprovement. By April 1994, the
rash on the right hand had resolved, but his
left hand had a small lichenified, excoriated
area. He used a bronchodilator three morn-
ings perweekandafterexercise.
Past medical and occupational history.
The patient denied childhood skin or respi-
ratory problems and had never smoked. He
noticed tears in his eyes when he was
around cats. His identical twin got hives
after bee stings.
The patient first worked in auto shops
doing body work and painting. Then, as a
technical studentfor 2 years, he spray-painted
and refinished furniture. His most recent job
(for 4 years) involved spray-painting furniture
on an overhead conveyer belt, wearing a sol-
vent respirator without eye protection. He
stood between the furniture and the exhaust
ventwhenspraying the backofeach piece.
The painters added activator to the
paint in a small room with a wall fan. They
Address correspondence to D.K. Milton, 665
Huntington Avenue, Boston, MA 02115 USA.
Telephone: (617) 432-3324. Fax: (617) 432-0219.
E-mail: dmilton@hohp.hawvard.edu
Received 22 March 1999; accepted 22April 1999.
Environmental Health Perspectives X Volume 107, Number 7, July 1999 599in irnnmantd IL I9in . . '
wore rubber gloves when available, but no
respiratory protection.
Discussion
This patient, who had worked as a spray
painter, experienced asthma and dermatitis
shortly after beginning work with a new
aziridine cross-linker. Aziridines are three-
membered ring compounds with one nitro-
gen and include propyleneimine, ethyl-
eneimine, and polyfunctional aziridines (2).
Polyfunctional aziridine (PFA) compounds
are used as hardeners in industryandare syn-
thesized from two components (Figure 1).
The first is an aziridine, either ethyleneimine
or propyleneimine. The second component
is a multifunctional acrylate such as
trimethylolpropane triacrylate (TMPTA) or
pentaerythritol triacrylate (2). The specific
PFA hardener in this case, polyfunctional
aziridine cross-linker CX-100, is acopolymer
of propyleneimine and TMPTA (1). The
cross-linker is reportedly not contaminated
with free TMPTA (1). PFA hardeners may
be contaminated with free N,N-dimethyl-
ethanolamine andpropyleneimine (2.
Mono- and polyfunctional aziridines
have both irritating and sensitizing proper-
ties. Ethylenimine (C2H5N), commonly
termed "aziridine," is irritating to eyes, skin,
and mucous membranes. Ethylenimine
vapors can cause swelling of the face,
mouth, eyelids, and throat. Ethylenimine
may cause delayed upper and lower respira-
tory tract irritation, conjunctivitis, vomiting,
coughing (3), pulmonary edema, laryngeal
edema, and secondary bronchial pneumo-
nia. Fatal ethylenimine intoxication has
been reported (2) and may follow rapid skin
absorption. Ethylenimine is askin sensitizer,
which causes allergic contactdermatitis (2).
Propyleneimine alone has not been
reported to cause allergic reactions (2).
Although propyleneimine or a related
hardener was suspected ofcausing six cases
ofbronchiolitis obliterans organizing pneu-
monia (BOOP) (2), the clinical features of
this case were more suggestive ofasthma, as
noted below.
The aziridine cross-linker is a potent
skin irritant and may cause contact sensiti-
zation. Closely related compounds have
been implicated as causative agents in con-
tact dermatitis from dental mold com-
pounds. Skin sensitization to the cross-linker
can be demonstrated with patch testing
(1,2. In two recent reports (2,4), PFA hard-
eners were associated with allergic contact
dermatitis in four patients, occupational
asthma in four patients, and both condi-
tions in an additional three patients. Three
patients were painters, and one of these
was a spray painter with asthma (2).
Immunologically mediated occupational
asthma was confirmed with specific bron-
choprovocation tests.
Taken together, epidemiologic studies
suggest a trend toward an increased risk of
asthma in painters, specifically spraypainters.
A Singapore case-control study identified no
increase in risk ofasthma in painters (5). A
surveillance program in the UnitedKingdom
concluded that the asthma rate was elevated
in all painters and that spray painters had a
rate ofoccupational asthma 30 times that of
the general population (6). Male Swedish
painters and laquerers had a nonsignificant
trend toward an increase in asthma mortali-
ty, with a standardized mortality ratio of
1.31 and a 95% confidence interval (CI) of
0.54-2.09 (2). Kogevinas etal. (8) reported a
trend toward an increased risk ofasthma in
both spray painters (odds ratio = 4.83; CI,
0.92-25.39) and non-spray painters. The
effect measures were higher for spray
painters than for other painters when
bronchial reactivity was included in the case
definition, but the sample sizes were small.
A subsequent study from New Zealand did
not report an increased risk ofwheezing in
either group of painters, but spray painters
exhibited a trend toward increased bronchial
hyperresponsiveness (9).
Painters may be exposed to a variety of
other agents that can cause occupational
asthma, including isocyanates, alkyd resins,
and chromates (10). Perhaps the most com-
mon exposures that may cause asthma in
painters are diisocyantes such as toluene
diisocyante, isophorone diisocyanate, hexa-
methylene diisocyanate (HDI), and prepoly-
mers of HDI (10). In one surveillance pro-
gram, isocyanates were the reported causal
agent in 22.2% ofoccupational asthma, and
28% ofisocyanate-induced cases occurred in
painters (6). The case described here
involved exposure to toluene diisocyanate,
which causes bronchial asthma, skin irrita-
tion, and allergic eczema. In this case, the
symptom onset coincided with exposure to
another agent, but it is possible that long-
term exposure to diisocyanates was a con-
tributory sensitizing factor. The mean laten-
cy in those who have isocyanate-associated
asthma between startingwork and symptom
onset is 7 years (11).
The importance of occupational expo-
sures as causes ofasthmais underappreciated.
Estimates fromsurveillance studies (6,12) are
low because physicians often do not ask
about or report an occupational component.
Community-based cross-sectional studies
offer somewhat higher estimates (8,9), but
because of narrowly defined exposures, the
attributable risks must still be regarded as
lower bounds (13). A clinic-based case-con-
trol study found that the attributable risk of
asthma due to manufacturing or servicework
was 33% (5). A health maintenance organi-
zation-based prospective study of adult-
onset asthma, which examined both the
potential occupational exposures and the
relation of symptoms to the workplace,
found that occupational exposure accounted
for 21% of clinically significant adult-onset
asthma cases (14).
In many instances, immunologically
mediated occupational asthma causes pro-
longed disability due to chronic airway
inflammation (15). The improvement in
respiratory function in the current case may
have resulted from the relatively short dura-
tion ofexposure. Earlyworkplace removal is
associated with a better prognosis (15). By 2
Figure 1. Chemical structure of compounds used
in the manufacture of paint products.
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years after workplace removal, function will
have reached a plateau and an evaluation of
permanent impairment and disability can be
conducted (15).
The diagnosis of occupational asthma is
based on acombination ofhistoryandobjec-
tive tests (15,16). The history indudes typi-
cal respiratory symptoms associated with
working and exposure to agents known to
cause asthma. It maybe less apparent that ill-
ness is work-related when symptoms occur
in response to nonspecific irritants and are
severe enough to last through the weekends
(16). The objective tests include serial pul-
monary function testing to document vari-
able airflow limitation and challenges to
pharmacologic agents or the specific agent in
question. Challenge tests can be falsely nega-
tive after the worker leaves the workplace for
several days. Skin tests or radioallergosorbent
tests for serum antibodies can establish sensi-
tization to some agents, most ofwhich are of
high-molecularweight (15), such as latex.
The pattern observed on pharmacologic
challenge is associated with the etiologic
agent and the immunologic mechanism
(15,16) (Table 1). Immunologically mediat-
ed asthma involves at least a short latency
period. High-molecular weight agents
(. 5,000 daltons) cause asthmaby induction
ofIgE antibodies (15). Some low-molecular
weight agents such as acid anhydrides and
platinum salts combinewith a native protein
to induce IgE antibodies. IgE-dependent
reactions can involve an early asthmatic
reaction, between several minutes and 2 hr
after exposure (15). Most low-molecular
weight agents cause asthma through an IgE-
independent immunologic mechanism. IgE-
independent responses often involve a late
asthmatic reaction, occurring between 4 and
48 hr after exposure. Biphasic responses,
Table 1. Common causes of occupational asthma.
Agent Workers at risk
High-molecular weight agents
Cereals Bakers, millers
Animal-derived allergens Animal handlers
Enzymes Detergent users, pharmaceutical workers, bakers




Isocyanates Spray painters; insulation installers; manufacturers of plastics,
rubbers, foam
Wood dusts Forestworkers, carpenters, cabinetmakers
Anhydrides Users of plastics, epoxy resins





Formaldehyde, glutaraldehyde Hospital staff
Acrylate Adhesives handlers
Drugs Pharmaceutical workers, health professionals
Metals Solderers, refiners
Reprinted from Chan-Yeung ( 15) with permission from the Massachusetts Medical Society. Copyright © 1995
Massachusetts Medical Society. All rights reserved.
consisting of both early and late reactions,
can occur following exposure to agents con-
sidered either IgE dependent or IgE inde-
pendent (15). Irritants, such as chlorine, can
cause asthma without latency through unde-
termined mechanisms (15,17,18).
The differential diagnosis includes
several other respiratory conditions, includ-
ing hypersensitivity pneumonitis (HP) and
BOOP. HP, also termed extrinsic allergic
alveolitis, can occur with chronic exposure
to certain agents that also cause occupa-
tional asthma, such as diisocyanates.
Although late HP is classically associated
with a restrictive pattern on pulmonary
function testing, HP can also cause small
airways obstruction. The chest radiograph
in chronic HP will generally involve a dif-
fuse reticulonodular infiltrate, but may be
normal early in the disease. Fever and other
systemic symptoms are common, but are
not always seen. Exposure to an agent that
causes HP can sometimes be confirmed by
checking for serum precipitins. Definitive
diagnosis can be made by bronchoalveolar
lavage or lung biopsy.
BOOP is often idiopathic, and frequent-
ly results in features not observed in this
case, such as leukocytosis, crackles on lung
auscultation, a restrictive pattern on pul-
monary function testing, and patchy infil-
trates on the chest radiograph. However,
BOOP was not definitively excluded, given
that the drops in the peak flow rate associat-
ed with work were small and no biopsy was
performed. The positive methacholine
response does not exclude BOOP, given
that certain exposures can cause both
BOOP and nonspecific bronchial hyperre-
activity (19).
This case demonstrates the importance
of proper work practices. Rubber gloves
were not always available. The patient did
not wear a respirator during the mixing
process. The respirator the patient wore
during painting was designed to protect
against solvents, as opposed to particulates.
Moreover, the respirator did not protect
the eyes. In addition, if the worker had
been able to rotate the piece being painted,
it would not have been necessary for him
to be located between the paint being
sprayed and the ventilation exhaust.
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